The United States DNA polymerase market is projected to reach USD 246.9 million by 2035, supported by rising investments in ...

Biomaterials have evolved from passive structural scaffolds to active intelligent systems that dynamically interact with the biological environment. Recent ...

The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Goldenberries taste like a cross between pineapple and mango, pack the nutritional punch of a superfood, and are increasingly ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Scientists grew a microscopic fungus into a more efficient — and meat-like — edible protein by tweaking just two genes with ...

A session at the AHA Scientific Sessions 2025 focused on the latest groundbreaking trails in cardiometabolic therapies.

Challenger, Gray & Christmas said layoff plans totaled 71,321 in November, a step down from the massive cuts announced in ...

For the scientific enterprise, 2025 was marked by setbacks and challenges. But scientists are no strangers to adversity—the ability to overcome obstacles is built into our training. In turn, research ...

Nearly three decades since the remarkable cloning of Dolly the sheep, it has all gone quiet on the human cloning front.

Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...